PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Cannabis (medicinal) - Epilepsy

PAD Profile : Cannabis (medicinal) - Epilepsy Important

Keywords :
CBD, CBMP, cannabis, Dravet syndrome, Lennox-Gastaut syndrome, Cancard, Cannabis-based products for medicinal use, CBPM
Brand Names Include :
Epidyolex
Important Information :
Specialist centres only (including ongoing supply)

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Oral solution
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 November 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

NHS England guidance to support clinicians on the prescribing of cannabis-based products for medicinal use:

https://www.england.nhs.uk/medicines-2/support-for-prescribers/cannabis-based-products-for-medicinal-use/

16 January 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee (APC) notes that NHS England routinely commissions cannabidiol for epilepsy in line with NICE TAs 614 and 615.

When cannabidiol is not being used in combination with clobazam, funding is via individual funding request (IFR) through NHS England.

Cannabidiol for epilepsy other than Lennox-Gastaut syndrome / Dravet syndrome: The APC confirmed that this would currently be an off-label / unlicensed use of a product with limited evidence for clinical efficacy or cost effectiveness. Clinicians who fulfil the legal criteria for the prescription of cannabidiol and who wish to prescribe it should check the responsible commissioner's Individual Funding Request (IFR) policy for more details.

PLEASE NOTE: only those centres commissioned to provide adult specialist neuroscience services or specialist neuroscience services for children should be prescribing cannabidiol for epilepsy. (See the specialised service letter SSC2111 (23rd December 2019) for further information and for lise of commissioned specialist centres).

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Associated BNF Codes

04. Central Nervous System
04.08.01. Control of epilepsy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More